BioWorld

Dec. 14, 2009

View Archived Issues

Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain

Roche subsidiary Genentech Inc. and Biogen Idec Inc. said their first Phase III trial with anti-CD20 antibody ocrelizumab achieved its primary endpoint of improving ACR20 scores in rheumatoid arthritis patients. (BioWorld Today) Read More

Dendreon: $356M Sale to Make Provenge, Gear Up for Launch

Read More

Genentech Pact Kaput, SeaGen Revs Effort with Lead Candidate

Read More

MiR-206 Affecting Nerve-Muscle Connection to Slow Down ALS

Read More

Universal Vaccine: 'End-Game' Pursuit to Counter Flu Pandemic

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Bench Press

Read More